Early-Study of drug combos for rare blood cancer halted
NCT ID NCT04810611
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 29 times
Summary
This early-phase study aimed to find safe doses of certain drug combinations for adults with a mild form of myelodysplastic syndrome (MDS), a blood cancer. Researchers planned to enroll 33 participants to monitor side effects and treatment adjustments. However, the study was terminated before completion, so no final conclusions were drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City Of Hope National Med Center Oncology
Duarte, California, 91010, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
MD Anderson Cancer Center/University of Texas MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital .
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Prahran, Victoria, 3181, Australia
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Salamanca, Castille and León, 37007, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
The Ohio State University Wexner Medical Center .
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.